Linezolid

Linezolid
(lah nez’ oh lid)
Zyvox
PREGNANCY CATEGORY C
Drug class
Oxazolidinone antibiotic
Therapeutic Actions
Bacteriostatic and bacteriocidal: Interferes with protein synthesis on the bacterial ribosome; effective in VRE, Staphylococcus, and methicillin-resistant S. aureus (MRSA) and penicillin-resistant pneumococci and S. aureus; is a reversible, nonselective MAOI.
Indications
  • Treatment of infections due to vancomycin-resistant Enterococcus faecium (VREF)
  • Treatment of nosocomial and community-acquired pneumonia due to S. aureus and penicillin-susceptible Streptococcus pneumoniae
  • Treatment of complicated and uncomplicated skin and skin-structure infections including those caused by MRSA
  • Treatment of diabetic foot infections without osteomyelitis caused by gram-positive organisms including MRSA, Streptococcus pyogenes, or Streptococcus agalactiae
Available Forms
Tablets—600 mg; powder for oral suspension—100 mg/5 mL; injection—2 mg/mL
Dosages
No dosage adjustment is needed if switching between oral and IV forms.
Adults and children 12 yr and older
  • VREF, MRSA, pneumonia, complicated skin and skin structure infections, including diabetic foot ulcers without osteomyelitis: 600 mg IV or PO every 12 hr for 10–28 days, depending on infection.
  • Uncomplicated skin and skin structure infections: 400 mg PO every 12 hr for 10–14 days.
Pediatric patients
  • VREF, CAP, nosocomial pneumonia, complicated skin, and skin structure infections: 11 yr or younger: 10 mg/kg IV or PO every 8 hr for 10–14 days.
  • Uncomplicated skin and skin-structure infections: 5–11 yr: 10 mg/kg PO every 12 hr for 10–14 days. Younger than 5 yr: 10 mg/kg PO every 8 hr.
Pharmacokinetics
Route Onset Peak
Oral Rapid 1–2 hr
IV Rapid 30 min

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Linezolid

Full access? Get Clinical Tree

Get Clinical Tree app for offline access